214 related articles for article (PubMed ID: 36449569)
1. SDHx mutation and pituitary adenoma: can in vivo 1H-MR spectroscopy unravel the link?
Branzoli F; Salgues B; Marjańska M; Laloi-Michelin M; Herman P; Le Collen L; Delemer B; Riancho J; Kuhn E; Jublanc C; Burnichon N; Amar L; Favier J; Gimenez-Roqueplo AP; Buffet A; Lussey-Lepoutre C
Endocr Relat Cancer; 2023 Feb; 30(2):. PubMed ID: 36449569
[TBL] [Abstract][Full Text] [Related]
2. Germinal defects of SDHx genes in patients with isolated pituitary adenoma.
Mougel G; Lagarde A; Albarel F; Essamet W; Luigi P; Mouly C; Vialon M; Cuny T; Castinetti F; Saveanu A; Brue T; Barlier A; Romanet P
Eur J Endocrinol; 2020 Oct; 183(4):369-379. PubMed ID: 32621582
[TBL] [Abstract][Full Text] [Related]
3. Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice.
Xekouki P; Szarek E; Bullova P; Giubellino A; Quezado M; Mastroyannis SA; Mastorakos P; Wassif CA; Raygada M; Rentia N; Dye L; Cougnoux A; Koziol D; Sierra Mde L; Lyssikatos C; Belyavskaya E; Malchoff C; Moline J; Eng C; Maher LJ; Pacak K; Lodish M; Stratakis CA
J Clin Endocrinol Metab; 2015 May; 100(5):E710-9. PubMed ID: 25695889
[TBL] [Abstract][Full Text] [Related]
4. Succinate detection using in vivo
Lussey-Lepoutre C; Bellucci A; Burnichon N; Amar L; Buffet A; Drossart T; Fontaine S; Clement O; Benit P; Rustin P; Groussin L; Meatchi T; Gimenez-Roqueplo AP; Tavitian B; Favier J
Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1510-1517. PubMed ID: 31834447
[TBL] [Abstract][Full Text] [Related]
5. In Vivo Detection of Succinate by Magnetic Resonance Spectroscopy as a Hallmark of SDHx Mutations in Paraganglioma.
Lussey-Lepoutre C; Bellucci A; Morin A; Buffet A; Amar L; Janin M; Ottolenghi C; Zinzindohoué F; Autret G; Burnichon N; Robidel E; Banting B; Fontaine S; Cuenod CA; Benit P; Rustin P; Halimi P; Fournier L; Gimenez-Roqueplo AP; Favier J; Tavitian B
Clin Cancer Res; 2016 Mar; 22(5):1120-9. PubMed ID: 26490314
[TBL] [Abstract][Full Text] [Related]
6. Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC-PGL syndromes: a clinicopathological and molecular analysis.
Papathomas TG; Gaal J; Corssmit EP; Oudijk L; Korpershoek E; Heimdal K; Bayley JP; Morreau H; van Dooren M; Papaspyrou K; Schreiner T; Hansen T; Andresen PA; Restuccia DF; van Kessel I; van Leenders GJ; Kros JM; Looijenga LH; Hofland LJ; Mann W; van Nederveen FH; Mete O; Asa SL; de Krijger RR; Dinjens WN
Eur J Endocrinol; 2014 Jan; 170(1):1-12. PubMed ID: 24096523
[TBL] [Abstract][Full Text] [Related]
7. Serum Succinate/Fumarate Ratio in Patients With Paraganglioma/Pheochromocytoma Attending an Endocrine Oncogenetic Unit.
Bancel LP; Masso V; Dessein AF; Aubert S; Leteurtre E; Coppin L; Odou MF; Cao CD; Cardot-Bauters C; Pigny P
J Clin Endocrinol Metab; 2023 Aug; 108(9):2343-2352. PubMed ID: 36848172
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of the oncometabolite succinate in SDHx-mutation carriers.
Eijkelenkamp K; Osinga TE; Links TP; van der Horst-Schrivers ANA
Clin Genet; 2020 Jan; 97(1):39-53. PubMed ID: 30977114
[TBL] [Abstract][Full Text] [Related]
9. An aggressive cabergoline-resistant, temozolomide-responsive macroprolactinoma due to a germline
Alzahrani AS; Bin Nafisah A; Alswailem M; Moria Y; Poprawski D; Al-Hindi H; Pacak K
Front Endocrinol (Lausanne); 2023; 14():1273093. PubMed ID: 38152133
[TBL] [Abstract][Full Text] [Related]
10. Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency.
Richter S; Peitzsch M; Rapizzi E; Lenders JW; Qin N; de Cubas AA; Schiavi F; Rao JU; Beuschlein F; Quinkler M; Timmers HJ; Opocher G; Mannelli M; Pacak K; Robledo M; Eisenhofer G
J Clin Endocrinol Metab; 2014 Oct; 99(10):3903-11. PubMed ID: 25014000
[TBL] [Abstract][Full Text] [Related]
11. The 3PAs: An Update on the Association of Pheochromocytomas, Paragangliomas, and Pituitary Tumors.
Xekouki P; Brennand A; Whitelaw B; Pacak K; Stratakis CA
Horm Metab Res; 2019 Jul; 51(7):419-436. PubMed ID: 30273935
[TBL] [Abstract][Full Text] [Related]
12. 3P association (3PAs): Pituitary adenoma and pheochromocytoma/paraganglioma. A heterogeneous clinical syndrome associated with different gene mutations.
Guerrero-Pérez F; Fajardo C; Torres Vela E; Giménez-Palop O; Lisbona Gil A; Martín T; González N; Díez JJ; Iglesias P; Robledo M; Villabona C
Eur J Intern Med; 2019 Nov; 69():14-19. PubMed ID: 31431315
[TBL] [Abstract][Full Text] [Related]
13. Succinate: A Serum Biomarker of SDHB-Mutated Paragangliomas and Pheochromocytomas.
Lamy C; Tissot H; Faron M; Baudin E; Lamartina L; Pradon C; Al Ghuzlan A; Leboulleux S; Perfettini JL; Paci A; Hadoux J; Broutin S
J Clin Endocrinol Metab; 2022 Sep; 107(10):2801-2810. PubMed ID: 35948272
[TBL] [Abstract][Full Text] [Related]
14. Familial SDHA mutation associated with pituitary adenoma and pheochromocytoma/paraganglioma.
Dwight T; Mann K; Benn DE; Robinson BG; McKelvie P; Gill AJ; Winship I; Clifton-Bligh RJ
J Clin Endocrinol Metab; 2013 Jun; 98(6):E1103-8. PubMed ID: 23633203
[TBL] [Abstract][Full Text] [Related]
15. Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel-Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127).
Gupta S; Zhang J; Milosevic D; Mills JR; Grebe SK; Smith SC; Erickson LA
Endocr Pathol; 2017 Sep; 28(3):253-268. PubMed ID: 28646318
[TBL] [Abstract][Full Text] [Related]
16. 15 YEARS OF PARAGANGLIOMA: The association of pituitary adenomas and phaeochromocytomas or paragangliomas.
O'Toole SM; Dénes J; Robledo M; Stratakis CA; Korbonits M
Endocr Relat Cancer; 2015 Aug; 22(4):T105-22. PubMed ID: 26113600
[TBL] [Abstract][Full Text] [Related]
17. Metabolome profiling by HRMAS NMR spectroscopy of pheochromocytomas and paragangliomas detects SDH deficiency: clinical and pathophysiological implications.
Imperiale A; Moussallieh FM; Roche P; Battini S; Cicek AE; Sebag F; Brunaud L; Barlier A; Elbayed K; Loundou A; Bachellier P; Goichot B; Stratakis CA; Pacak K; Namer IJ; Taïeb D
Neoplasia; 2015 Jan; 17(1):55-65. PubMed ID: 25622899
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
[TBL] [Abstract][Full Text] [Related]
19. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma.
Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J
J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498
[TBL] [Abstract][Full Text] [Related]
20. A review of the tumour spectrum of germline succinate dehydrogenase gene mutations: Beyond phaeochromocytoma and paraganglioma.
MacFarlane J; Seong KC; Bisambar C; Madhu B; Allinson K; Marker A; Warren A; Park SM; Giger O; Challis BG; Maher ER; Casey RT
Clin Endocrinol (Oxf); 2020 Nov; 93(5):528-538. PubMed ID: 32686200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]